Biogen Operating Expenses Growth & History (BIIB)
Biogen's operating expenses was $8.33B for fiscal 2025.
View full Biogen company overviewBiogen annual operating expenses history
| Fiscal year | Period ended | Operating expenses | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $8.33B | $564.2M | +7.26% |
| 2024 | 2024-12-31 | $7.77B | −$768.9M | −9.00% |
| 2023 | 2023-12-31 | $8.54B | $1.96B | +29.74% |
| 2022 | 2022-12-31 | $6.58B | −$1.56B | −19.15% |
| 2021 | 2021-12-31 | $8.14B | −$753.5M | −8.47% |
| 2020 | 2020-12-31 | $8.89B | $1.56B | +21.26% |
| 2019 | 2019-12-31 | $7.34B | −$229.0M | −3.03% |
| 2018 | 2018-12-31 | $7.56B | $636.2M | +9.18% |
| 2017 | 2017-12-31 | $6.93B | $631.0M | +10.02% |
| 2016 | 2016-12-31 | $6.30B | $424.3M | +7.22% |
| 2015 | 2015-12-31 | $5.87B | $125.1M | +2.18% |
| 2014 | 2014-12-31 | $5.75B | $2.19B | +61.50% |
| 2013 | 2013-12-31 | $3.56B | $443.8M | +14.25% |
| 2012 | 2012-12-31 | $3.12B | −$208.8M | −6.28% |
| 2011 | 2011-12-31 | $3.32B | −$143.6M | −4.14% |
| 2010 | 2010-12-31 | $3.47B | $385.6M | +12.51% |
| 2009 | 2009-12-31 | $3.08B | $198.0M | +6.87% |
| 2008 | 2008-12-31 | $2.88B | $492.1M | +20.57% |
| 2007 | 2007-12-31 | $2.39B | — | — |
Biogen quarterly operating expenses
| Fiscal quarter | Period ended | Operating expenses | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.48B | −$425.2M | −22.36% |
| Q1 2026 | 2026-03-31 | $2.10B | −$19.7M | −0.93% |
| Q4 2025 | 2025-12-31 | $2.34B | $172.2M | +7.96% |
| Q3 2025 | 2025-09-30 | $1.98B | −$37.4M | −1.86% |
| Q2 2025 | 2025-06-30 | $1.90B | $135.3M | +7.66% |
| Q1 2025 | 2025-03-31 | $2.12B | $294.1M | +16.11% |
| Q4 2024 | 2024-12-31 | $2.16B | $68.5M | +3.27% |
| Q3 2024 | 2024-09-30 | $2.01B | −$656.7M | −24.58% |
| Q2 2024 | 2024-06-30 | $1.77B | $18.3M | +1.05% |
| Q1 2024 | 2024-03-31 | $1.83B | −$199.0M | −9.83% |
| Q4 2023 | 2023-12-31 | $2.09B | −$108.8M | −4.94% |
| Q3 2023 | 2023-09-30 | $2.67B | $1.53B | +134.88% |
| Q2 2023 | 2023-06-30 | $1.75B | $428.3M | +32.46% |
| Q1 2023 | 2023-03-31 | $2.02B | $103.6M | +5.39% |
| Q4 2022 | 2022-12-31 | $2.20B | $56.8M | +2.65% |
| Q3 2022 | 2022-09-30 | $1.14B | −$847.5M | −42.70% |
| Q2 2022 | 2022-06-30 | $1.32B | −$969.7M | −42.36% |
| Q1 2022 | 2022-03-31 | $1.92B | $201.0M | +11.69% |
| Q4 2021 | 2021-12-31 | $2.15B | −$1.04B | −32.56% |
| Q3 2021 | 2021-09-30 | $1.98B | −$304.8M | −13.31% |
| Q2 2021 | 2021-06-30 | $2.29B | $582.2M | +34.10% |
| Q1 2021 | 2021-03-31 | $1.72B | $5.7M | +0.33% |
| Q4 2020 | 2020-12-31 | $3.18B | $1.29B | +68.11% |
| Q3 2020 | 2020-09-30 | $2.29B | $495.9M | +27.65% |
| Q2 2020 | 2020-06-30 | $1.71B | $46.3M | +2.79% |
| Q1 2020 | 2020-03-31 | $1.71B | −$272.7M | −13.72% |
| Q4 2019 | 2019-12-31 | $1.89B | −$189.6M | −9.10% |
| Q3 2019 | 2019-09-30 | $1.79B | $52.4M | +3.01% |
| Q2 2019 | 2019-06-30 | $1.66B | −$482.5M | −22.51% |
| Q1 2019 | 2019-03-31 | $1.99B | $390.7M | +24.47% |
| Q4 2018 | 2018-12-31 | $2.08B | $242.4M | +13.17% |
| Q3 2018 | 2018-09-30 | $1.74B | $317.5M | +22.30% |
| Q2 2018 | 2018-06-30 | $2.14B | $265.9M | +14.16% |
| Q1 2018 | 2018-03-31 | $1.60B | −$189.6M | −10.62% |
| Q4 2017 | 2017-12-31 | $1.84B | −$143.7M | −7.24% |
| Q3 2017 | 2017-09-30 | $1.42B | −$106.6M | −6.97% |
| Q2 2017 | 2017-06-30 | $1.88B | $443.7M | +30.95% |
| Q1 2017 | 2017-03-31 | $1.79B | $437.6M | +32.45% |
| Q4 2016 | 2016-12-31 | $1.98B | $313.3M | +18.75% |
| Q3 2016 | 2016-09-30 | $1.53B | $124.5M | +8.85% |
| Q2 2016 | 2016-06-30 | $1.43B | $75.2M | +5.54% |
| Q1 2016 | 2016-03-31 | $1.35B | −$88.7M | −6.17% |
| Q4 2015 | 2015-12-31 | $1.67B | $185.6M | +12.50% |
| Q3 2015 | 2015-09-30 | $1.41B | $42.8M | +3.14% |
| Q2 2015 | 2015-06-30 | $1.36B | −$78.1M | −5.44% |
| Q1 2015 | 2015-03-31 | $1.44B | −$25.2M | −1.72% |
| Q4 2014 | 2014-12-31 | $1.49B | $672.3M | +82.66% |
| Q3 2014 | 2014-09-30 | $1.36B | $454.7M | +50.04% |
| Q2 2014 | 2014-06-30 | $1.44B | $370.4M | +34.73% |
| Q1 2014 | 2014-03-31 | $1.46B | $691.4M | +89.69% |
| Q4 2013 | 2013-12-31 | $813.3M | $247.0M | +43.61% |
| Q3 2013 | 2013-09-30 | $908.6M | $197.6M | +27.80% |
| Q2 2013 | 2013-06-30 | $1.07B | $151.0M | +16.50% |
| Q1 2013 | 2013-03-31 | $770.9M | −$151.8M | −16.45% |
| Q4 2012 | 2012-12-31 | $566.3M | −$351.3M | −38.28% |
| Q3 2012 | 2012-09-30 | $711.0M | −$110.5M | −13.45% |
| Q2 2012 | 2012-06-30 | $915.2M | $117.4M | +14.71% |
| Q1 2012 | 2012-03-31 | $922.6M | $135.6M | +17.23% |
| Q4 2011 | 2011-12-31 | $917.6M | $53.7M | +6.22% |
| Q3 2011 | 2011-09-30 | $821.4M | −$160.2M | −16.32% |
| Q2 2011 | 2011-06-30 | $797.8M | −$19.0M | −2.32% |
| Q1 2011 | 2011-03-31 | $787.1M | −$18.1M | −2.25% |
| Q4 2010 | 2010-12-31 | $863.9M | $120.2M | +16.16% |
| Q3 2010 | 2010-09-30 | $981.7M | $245.3M | +33.32% |
| Q2 2010 | 2010-06-30 | $816.8M | −$53.6M | −6.15% |
| Q1 2010 | 2010-03-31 | $805.2M | $73.6M | +10.07% |
| Q4 2009 | 2009-12-31 | $743.7M | — | — |
| Q3 2009 | 2009-09-30 | $736.3M | −$10.8M | −1.44% |
| Q2 2009 | 2009-06-30 | $870.4M | $173.7M | +24.94% |
| Q1 2009 | 2009-03-31 | $731.5M | — | — |
| Q3 2008 | 2008-09-30 | $747.1M | — | — |
| Q2 2008 | 2008-06-30 | $696.6M | — | — |
Biogen operating expenses trends
Over the last five fiscal years, Biogen's operating expenses decreased from $8.89B to $8.33B, a change of −$560.4M. The latest reported quarter, Q2 2026, shows $1.48B.
What operating expenses mean
Operating expenses are the recurring costs of running a company’s business beyond the direct costs used to calculate gross profit. They commonly include selling, general and administrative expenses, research and development, and other operating costs.
SEC-reported and calculated operating expenses
TickerStat uses operating expenses reported in company SEC filings when available. When a separate total is unavailable, it calculates operating expenses as aligned gross profit minus operating income for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biogen source filings ↗